Sigilon Therapeutics Inc (SGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 3,165 | 1,990 | 1,947 | 2,704 | 2,958 |
| Gross Profit | 3,165 | 1,990 | 1,947 | 2,704 | 2,958 |
| Operating Expenses | 16,642 | 19,281 | 21,686 | 22,743 | 21,525 |
| Operating Income | -13,477 | -17,291 | -19,739 | -20,039 | -18,567 |
| Interest Expense | 491 | 507 | 499 | 494 | 488 |
| Other Income | 109 | 53 | 82 | 96 | 82 |
| Pre-tax Income | -13,859 | -17,745 | -20,156 | -20,437 | -18,973 |
| Net Income Continuous | -13,859 | -17,745 | -20,156 | -20,437 | -18,973 |
| Net Income | $-13,859 | $-17,745 | $-20,156 | $-20,437 | $-18,973 |
| EPS Basic Total Ops | -5.59 | -7.15 | -8.19 | -8.45 | -7.80 |
| EPS Basic Continuous Ops | -5.57 | -7.13 | -8.18 | -8.42 | -7.84 |
| EPS Diluted Total Ops | -5.59 | -7.15 | -8.19 | -8.45 | -7.80 |
| EPS Diluted Continuous Ops | -5.57 | -7.13 | -8.18 | -8.42 | -7.84 |
| EPS Diluted Before Non-Recurring Items | -5.59 | -7.15 | -8.19 | N/A | N/A |
| EBITDA(a) | $-13,126 | $-16,986 | $-19,433 | $-19,776 | $-18,320 |